Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 14, 2017FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition
14 Feb 2017 KING OF PRUSSIA, Pa — 14 February 2017 Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the...
-
Feb 14, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Feb 10, 2017An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type...
-
Jan 19, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 19, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 11, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 9, 2017- CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A
09 Jan 2017 MARBURG, Germany — 09 January 2017 CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A The therapy has been specifically designed for greater...
-
Jan 9, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jan 5, 2017
05 Jan 2017 CAMBRIDGE, MA — 05 January 2017 Momenta to receive $50 million upfront license fee and up to 4550 million in potential milestone payments from CSL Momenta to host a conference call...
-
Dec 23, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases